Company profile for ILiAD Biotechnologies

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ILiAD Biotechnologies (ILiAD) is a clinical stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. Our lead candidate is BPZE1, a live attenuated pertussis vaccine that is currently being studied in two fully enrolled Phase 2 clinical trials. BPZE1 is the most advanced next generation pertussis vaccine and has successfully completed two Phase 1 clinical studies. ILiAD Bio...
ILiAD Biotechnologies (ILiAD) is a clinical stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. Our lead candidate is BPZE1, a live attenuated pertussis vaccine that is currently being studied in two fully enrolled Phase 2 clinical trials. BPZE1 is the most advanced next generation pertussis vaccine and has successfully completed two Phase 1 clinical studies. ILiAD Biotechnologies, LLC is a registered Delaware company founded in 2012.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Greater New York Area, East Coast, Northeastern US
Telephone
Telephone
954-336-0777
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20250127208008/en

BUSINESSWIRE
27 Jan 2025

https://www.businesswire.com/news/home/20241001001881/en

BUSINESSWIRE
01 Oct 2024

https://www.businesswire.com/news/home/20240802092354/en

BUSINESSWIRE
05 Aug 2024

https://www.contractpharma.com/contents/view_breaking-news/2024-06-24/iliad-selects-emmes-group-to-conduct-phase-iii-studies-of-pertussis-vaccine-candidate/9769

CONTRACT PHARMA
24 Jun 2024

https://www.businesswire.com/news/home/20240528492826/en

BUSINESSWIRE
28 May 2024
ILiAD's pertussis shot joins Trojan horse of childhood vaccines
ILiAD's pertussis shot joins Trojan horse of childhood vaccines

28 May 2024

// Annalee Armstrong FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/iliads-pertussis-shot-successfully-joins-trojan-horse-childhood-vaccines-phase-2

Annalee Armstrong FIERCE BIOTECH
28 May 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty